Zymeworks (ZYME) Equity Average (2021 - 2026)

Zymeworks has disclosed Equity Average across 6 years of filings, most recently posting $216.0 million for Q1 2026.

• Equity Average for Q1 2026 came in at $216.0 million, down 34.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $216.0 million (down 34.9% YoY), and the FY2025 annual result was $303.6 million, down 24.43% from the prior year.
• Equity Average came in at $216.0 million for Q1 2026 at Zymeworks, down from $294.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $483.2 million in Q1 2023 to a low of $201.0 million in Q3 2022.
• The 5-year median for Equity Average is $336.4 million (2022), against an average of $352.5 million.
• Across the five-year window, Equity Average surged 117.21% in 2023 and tumbled 34.9% in 2026, its largest moves.
• Zymeworks' Equity Average stood at $336.4 million in 2022, then jumped by 32.17% to $444.6 million in 2023, then fell by 20.63% to $352.9 million in 2024, then fell by 16.6% to $294.3 million in 2025, then slipped by 26.59% to $216.0 million in 2026.
• The last three Equity Average figures came in at $216.0 million (Q1 2026), $294.3 million (Q4 2025), and $327.3 million (Q3 2025), per Business Quant data.